Telesis Pharma B.V.

Better Drug Synthesis

2019-SARS-CoV-2 compounds

Highly active antiviral 2019-SARS-CoV-2 compounds for
your Coronavirus research and development

2019-SARS-CoV-2 compounds

This probe compound ML188 shows potent enzyme inhibition activity (3C-like protease, 3CLpro) and cellular antiviral activity.

Unlike the majority of reported coronavirus 3CLpro inhibitors that act via covalent modification of the enzyme, ML188 is a noncovalent SARS-CoV 3CLpro inhibitor with moderate MW and good enzyme and antiviral inhibitory activity.

Both, the active enantiomer and the inactive enantiomer are available as reference compounds.

Macbook Video Underlay

About

Mission & Vision
Responsive Layout

Company

Telesis Pharma BV is a pharmaceutical company working on the processes and chemistry of drugs. We are developing improved drug synthesis to reduce costs significantly while maintaining the high quality standards. This way we help our customers offer highly competitive drug products and therefore contribute to the accessibility of medicine to all.

Retina Graphics

Goals

It is Telesis aim to become a recognized drug synthesis company through ‘building’ on the current state-of-the-art MCR know-how and related licensed IP. Being an important link in the chain ‘from raw materials to marketed drug’ Telesis is focused on co-maker- and partnership relations. Telesis will commit to the highest environmental and quality standards.

Powerful Performance

Future

With a highly motivated and competent team Telesis wants to expand the company after the adaptation of its first drug process in the market by hiring additional people and working on subsequent classes of drugs. The technology oriented organization strives to a complementary skilled team to further expand the possibilities of the MCR technology and to optimize return of investment for all stakeholders.

Strategy & Implementation
Responsive Layout

High-end Generic Drug Market

Following an analysis of the Telesis technology proposition and the pharma market environment it is decided by the Telesis team to focus it’s initially commercialization efforts on the ‘high-end’ generic drug market.

Retina Graphics

Fee for Service

Telesis also wants to explore its capabilities in an earlier phase to reduce the dependence on (long-term) external financing. Within its primarily focal area Telesis will seek for commercial partners’ interest in a full or partial role for its MCR technology applicable to the partners’ molecule of choice. This way projects can be generated with on the bases a ‘fee for service’ structure and potential future income from tech transfer, royalties or else. In this respect it is important to have access to a kg scale facility. This is part of Telesis defined strategy.

Powerful Performance

Drug Discovery Developments

Telesis capabilities and IP assets could also be used in drug discovery developments utilizing the versatility of scaffolds following the two-way use of MCR technology. This may bring Telesis ‘on board’ of next generation medicine and associated processes to manufacture these drugs.

Telesis Pharma Team

Our Team Members
John Doe

Alexander
DÖMLING

FOUNDER & ADVISOR

He has held the chair for Drug Design at the University of Groningen since 2011. He studied chemistry and biology at the Technische Universität München (Germany) and obtained his PhD under the guidance of Prof. Ivar Ugi. After postdoctoral research under a Humboldt fellowship in the group of Nobel laureate Barry Sharpless, he founded the biotech companies Morphochem and later Carmolex Inc. After his habilitation he worked as full professor at the University of Pittsburgh in the School of Pharmacy.

Josh Clark

CONSTANTINOS
NEOCHORITIS

CEO

He received his PhD in 2011 in Organic Chemistry in the Department of Chemistry at Aristotle University of Thessaloniki. In June 2012 he joined the research group of Prof. Alexander Dömling in the Drug Design Group at the University of Groningen. His research interests include bioactive heterocycles, drug design, multicomponent reactions, and high throughput synthesis. He has published more than 26 peer-reviewed papers with 12 years’ experience in the field.

Mary Jane

PRAVIN
PATIL

CTO

Chemist in the Drug Design Group of the University of Groningen, highly skilled organic chemist with over 13 years of industrial R&D and academic research experience with pharmaceutical firms in India. He is expert in MCR chemistry and an experienced pilot plan chemist having performed multiple kg-lab syntheses. Additionally, Saroglitazar (Lipaglyn®) is a drug for the treatment of type 2 diabetes mellitus and dyslipidemia is approved for use in India by the Drug Controller General of India, was discovered and developed in his group.

Nix Maxwell

TRYFON ZARGANIS
-TZITZIKAS

CSO

He obtained his B.Sc. degree in Chemistry from the Aristotle University of Thessaloniki in 2010. In March 2012 he received his M.Sc. degree with an emphasis on organic chemistry from the Aristotle University of Thessaloniki. Since July 2012 he has been pursuing his Ph.D. in medicinal chemistry under the guidance of Prof. Alexander Dömling in the Drug Design Group at the University of Groningen, Netherlands. He has published more than 12 peer-reviewed papers.